Saturday, June 20, 2026
No article body is available. The title hints at a Novo Nordisk hacking story and an FDA reversal, but no facts can be confirmed.
Eli Lilly's pill version of orforglipron (Foundayo) beat Novo Nordisk's semaglutide pill at lowering blood sugar and weight loss in three large diabetes trials. Foundayo showed bigger drops in A1C levels and weight compared to the competing drug.
Lilly's orforglipron pill beat Novo's semaglutide pill on blood sugar and weight in three trials. That puts Lilly in a strong spot in the oral diabetes drug race.
Eli Lilly's retatrutide, a weight-loss drug that works three different ways in the body, helped people in a major trial lose about one-quarter of their body weight. This result may be stronger than what competitors like Novo Nordisk have shown with their own weight-loss drugs.
Retatrutide hit its Phase 3 goal with around 25% body weight loss. That may top Novo Nordisk's drugs and puts Lilly in a strong spot in the obesity market.
Maryland's state drug board set a price cap on Ozempic (a weight-loss and diabetes drug made by Novo Nordisk). Nine states are trying similar rules to make expensive drugs cost less for patients.
Maryland capped Ozempic's price. If more of the 9 states doing this succeed, Novo Nordisk gets paid less per dose across the US.
Eli Lilly released results from two late-stage trials showing that people who switched from higher-dose Wegovy or Zepbound to lower doses of Lilly's Foundayo pill or lower-dose Zepbound kept nearly all their weight loss over one year. The trials suggest the lower doses work well enough to maintain results when people switch from stronger versions.
Lilly's pill Foundayo may let patients step down from high-dose shots and keep their weight off. That could pull patients away from Novo's Wegovy.
A blood test that predicts GLP-1 response could help doctors pick the right patients. No data is available yet to judge how real or useful this test is.
Amazon selling Ozempic pills could push Novo to lower prices. If patients shop around more, Novo may earn less per sale.
Novo Nordisk's pill versions of semaglutide (sold as Ozempic for diabetes and Wegovy for weight loss) are now available on Amazon with same-day delivery. This expands how patients can buy these drugs, moving beyond traditional pharmacies.
Novo is making it easier to get its weight-loss and diabetes pills. Buying on Amazon could pull sales away from drugstores like CVS and Walgreens.
Amazon and Novo Nordisk teamed up to deliver the Ozempic pill version on the same day in some areas. This deal makes it easier for people to get the weight-loss drug without waiting.
Same-day delivery makes Novo's oral semaglutide easier to get. That could help Novo win patients who want a pill instead of Lilly's shots.
Novo lifted its 2026 outlook, but the real growth picture for Ozempic and Wegovy maker may be weaker than the headline number suggests.
Amazon Pharmacy now delivers semaglutide (Ozempic) pills and lets customers pick them up at offices. This makes the weight-loss drug easier to get through a major online retailer.
Amazon now ships Novo's Ozempic pills and offers in-office pickup. That gives Novo a bigger sales channel and makes the drug easier for patients to get.
No article body is available, so no specific facts can be confirmed about the Lilly vs. Novo competition story.
Novo Nordisk reported a 40% jump in semaglutide sales in India. The growth shows strong demand for the weight-loss drug in a major emerging market.
India is a huge new market for weight-loss drugs. Strong sales there help Novo make up for tougher competition from Lilly in the US.
Eli Lilly's Foundayo (tirzepatide pill) hit 7,335 prescriptions in its fourth week on the market. The new drug is selling slower than Novo Nordisk's Wegovy, a competing weight-loss injection.
Lilly's new weight-loss pill is off to a slow start. Novo's Wegovy shot is still outselling it, so Novo keeps the lead in the obesity drug market.
Novo Nordisk saw a big jump in Ozempic sales in India. The company is selling more of its semaglutide weight-loss drug in that market.
India is a huge new market for Novo. Strong early Ozempic sales there could help the company make up for lost ground against Lilly in the US.
Novo Nordisk's sales in India jumped 40% in April, even though generic versions of GLP-1 drugs (weight-loss and diabetes medicines) are now competing in the market. The growth shows strong demand for weight-loss drugs in India despite cheaper alternatives becoming available.
Novo's brand drugs still sell well in India even with cheaper copycats. That hints demand is strong enough to support both branded and generic GLP-1s.
Novo is growing fast in India, but cheaper generic copies are coming. That could squeeze prices and force Novo to defend its market there.
Novo Nordisk cut prices on Wegovy and Ozempic in India and saw sales jump 40% in April. The price cuts made the weight-loss and diabetes drugs more affordable in that market.
Lower prices in India helped Novo sell a lot more Wegovy and Ozempic. It shows price cuts can grow sales fast in big new markets.
Novo Nordisk's CEO says the pill form of Wegovy (semaglutide) is selling faster than ever in the United States. The company sees strong demand for the oral version of its weight-loss drug.
The Wegovy pill gives people a needle-free way to lose weight. Strong early sales help Novo defend its turf against Lilly's pills.
Novo Nordisk says its pill version of Wegovy (semaglutide) is on track to become a blockbuster drug, even as the weight-loss market fills up with competitors. The company is competing with other GLP-1 drugs like tirzepatide (Mounjaro) from Eli Lilly.
A pill form of Wegovy could be easier for patients than shots. Novo needs a hit to fight off Lilly's tirzepatide in the weight-loss market.
Amazon is now offering semaglutide (Ozempic) through self-service kiosks and same-day delivery. This move could change how people buy weight-loss drugs and shake up traditional pharmacy businesses.
Amazon selling Ozempic through kiosks and same-day delivery could pull weight-loss drug sales away from CVS and Walgreens.
Amazon will sell Novo's Ozempic pill. That makes it easier for people to get the drug, which could boost Novo's sales of the oral version.
Generic versions of semaglutide have captured about half the weight-loss drug market in India, but Novo Nordisk (which makes the brand-name version) remains a major seller there. The competition shows how cheaper copies are gaining share even as the original company keeps strong sales.
Generic semaglutide is taking half of India's weight-loss market. Novo still sells a lot, but cheap copies show what could happen in other countries when patents end.
Novo Nordisk cut the price of Ozempic in India, and sales of the weight-loss drug went up. Lower prices helped more people in India afford the medication.
Lower Ozempic prices in India helped more people buy it. This shows Novo can grow sales in new markets by charging less.
Novo Nordisk said its patent on semaglutide in China will not expire until 2027. This delay protects the company's ability to sell the drug exclusively in that market for several more years.
Novo keeps its China lock on semaglutide until 2027. That blocks cheap copies for two more years and protects Ozempic and Wegovy sales there.
Novo Nordisk's oral version of Wegovy (semaglutide pill) is being prescribed more often to new patients. The shift shows doctors are choosing the pill form instead of just the injection.
More doctors are picking the Wegovy pill for new patients. That could help Novo keep weight-loss sales as Lilly's pill rivals get closer to market.
Doctors may pick Novo's Wegovy pill over Lilly's pill version. That could help Novo keep more weight-loss patients as oral drugs hit the market.
A market report says GLP-1 drug sales could hit $180 billion by 2035. That points to years of strong growth for Novo and Lilly.
Novo Nordisk's stock outlook improved after its oral version of Wegovy (semaglutide) showed strong results. The company raised its financial forecast for 2026 based on this pill drug's success.
A pill version of Wegovy could reach more people than shots. Novo expects bigger sales in 2026, which helps it fight Lilly in the weight-loss market.
Novo Nordisk reported better-than-expected first-quarter profits, driven by strong sales of the pill form of Wegovy (a weight-loss drug). The company's oral semaglutide product is selling faster than Wall Street had predicted.
Novo's pill version of Wegovy is selling well. That gives Novo a stronger position against Lilly's weight-loss shots and helps it reach patients who don't want needles.